Kidney and bladder cancer surgery cost calculator

Kidney and bladder cancer surgery cost calculator helps estimate Korea-related cancer surgery, cancer drug, reimbursement, and treatment reserve scenarios in English.

Health cost scenario inputs

Enter Korea-related chronic care, eldercare, therapy, procedure, fertility, diagnostic, or medical tourism assumptions. Results are simplified planning estimates.

Treatment gross quote

₩20,000,000

Insurance or support amount

₩8,000,000

Estimated self-pay with reserve

₩16,200,000

Monthly reserve target

₩1,350,000

12 month plan

This English page is a simplified Korea-related health, eldercare, therapy, chronic disease, fertility, non-covered care, or medical tourism planning estimate. It is not medical advice and does not replace diagnosis, treatment decisions, insurer review, hospital quotes, or government benefit decisions.

Related calculators

Kidney and Bladder Cancer Surgery Cost Calculator

This calculator estimates the out-of-pocket cost of kidney cancer (renal cell carcinoma, C64) and bladder cancer (C67) treatment in Korea, the two main urologic cancers, and keeps the same pure calculation model as the Korean page. For kidney it covers partial nephrectomy (nephron-sparing), radical nephrectomy, robotic nephrectomy, and metastatic targeted or immunotherapy; for bladder it covers transurethral resection (TURBT), intravesical BCG, radical cystectomy with urinary diversion, and robotic cystectomy. Costs are split into covered and non-covered on 2026 Korean rules, and the model adds private indemnity reimbursement and the medical expense tax credit to reach a final self-pay figure.

Kidney cancer: nephron-sparing versus radical, and systemic therapy

Partial nephrectomy (nephron-sparing surgery) removes only the tumor with a margin and preserves the rest of the kidney; it is the standard for small T1 tumors and lowers the risk of chronic kidney disease and dialysis compared with removing the whole kidney. The model uses KRW 7,000,000 as the covered base fee (8-day stay), so the 5 percent special-case self-pay is roughly KRW 390,000 with the ward fee. Radical nephrectomy (KRW 9,000,000, 12-day stay) removes the whole kidney for larger or central tumors and can add a covered surcharge for inferior vena cava tumor-thrombus removal.

Robotic nephrectomy charges the robot surgery fee entirely out of pocket (about KRW 8,000,000 to KRW 15,000,000, KRW 12,000,000 average before regional and hospital adjustment; a major Seoul hospital lists robotic partial nephrectomy at KRW 14,000,000), while the covered surgery base is zero. Metastatic renal cell carcinoma is treated with systemic therapy that repeats over cycles: TKI targeted drugs (pazopanib, sunitinib) at about KRW 2,700,000 per 4-week cycle, the nivolumab plus ipilimumab immunotherapy combination (covered since September 2021) at about KRW 18,000,000 per 3-week cycle, and nivolumab maintenance at about KRW 3,000,000 per cycle.

  • Partial nephrectomy preserves renal function and is preferred for small tumors; robotic and laparoscopic approaches are common.
  • The robot fee is non-covered and never reduced by the cancer special-case program.
  • Systemic therapy is billed per cycle and repeated until progression; the model multiplies the per-cycle covered fee by the number of cycles.
  • Some regimens (first-line cabozantinib, pembrolizumab combinations) may be non-covered in 2026, so confirm coverage.

Bladder cancer: NMIBC versus MIBC is the central axis

The key fork in bladder cancer is whether the tumor invades the muscle layer. Non-muscle-invasive bladder cancer (NMIBC, about 75 percent of cases) is treated by transurethral resection of bladder tumor (TURBT), an endoscopic surgery with a short stay; the model uses KRW 2,200,000 covered (4-day stay), so the 5 percent self-pay is about KRW 130,000. High-risk NMIBC then receives intravesical BCG instillations, usually 6 weekly induction doses followed by maintenance for up to 1 to 3 years. BCG is billed per instillation (about KRW 150,000 covered, drug plus procedure), so the model treats it as a repeated per-instillation cost.

Muscle-invasive bladder cancer (MIBC) requires radical cystectomy with urinary diversion (ileal conduit or orthotopic neobladder), a major surgery with a 2 to 3 week stay. The model uses KRW 13,000,000 covered, so the 5 percent self-pay is about KRW 740,000, and a neobladder reconstruction can add a covered surcharge. Robotic cystectomy performs the resection and intracorporeal diversion minimally invasively but the robot fee is entirely self-pay (about KRW 10,000,000 to KRW 18,000,000). Neoadjuvant or perioperative gemcitabine-cisplatin chemotherapy is often given around cystectomy.

  • NMIBC: TURBT plus repeated BCG instillations, relatively low cost but frequent cystoscopic follow-up for recurrence.
  • MIBC: radical cystectomy plus urinary diversion, a large surgery with lifelong urostomy or neobladder management.
  • Cancer special-case patients are exempt from the long-stay copay increase (16+ days), which helps for the long cystectomy stay.

Cancer special-case copay and robotic-versus-covered comparison

Both kidney cancer (C64) and bladder cancer (C67) qualify for cancer special-case registration (code V193), which reduces the covered copay to 5 percent for 5 years when registered within 30 days of diagnosis (ordinary inpatient copay is 20 percent, and outpatient systemic therapy or BCG can be 30 to 60 percent). Crucially, the 5 percent rate applies only to covered items: it never applies to the non-covered robotic surgery fee, upper-grade room charges, pain-control injections, or non-covered drug combinations. The calculator shows a 20 percent versus 5 percent comparison so registration savings are explicit.

For surgical treatments, the calculator compares the fully self-paid robotic fee against the covered open and laparoscopic self-pay for the same cancer, so patients can weigh the extra robotic cost against its clinical benefit (bleeding, recovery, function preservation). The robot fee can also face private indemnity disputes, where the insurer argues the covered open or laparoscopic surgery was medically sufficient; keeping a specialist recommendation and medical-necessity documentation helps.

Indemnity, tax credit, and how to read the result

The estimate separates covered procedure fee, covered ward fee, robotic fee, room surcharge, pain-control injection, caregiver cost, private indemnity reimbursement, and the Korean medical expense tax credit (3 percent of salary threshold, 15 percent credit rate, with no KRW 7,000,000 cap for cancer patients as severe-disease patients under Income Tax Act Article 59-4). Surgeries are reimbursed as inpatient medical expenses, while outpatient systemic therapy and BCG may fall under per-visit outpatient limits; upper-grade rooms are typically reimbursed at 50 percent and caregiver cost is not reimbursed at all. The annual copay ceiling (about KRW 870,000 to KRW 8,430,000 by income decile in 2026) can refund excess covered copay.

Choose the cancer, then the treatment, stage, special-case registration, and either the surgical add-on (for surgery) or the regimen and repeat count (for systemic therapy or BCG). The result shows covered and non-covered self-pay, the repeated-treatment accumulation, the robotic-versus-covered comparison, the special-case 5 percent versus 20 percent comparison, and the final cost after indemnity and tax credit. This is a cost-planning estimate, not medical advice; public single-price tables do not exist for these surgeries, so figures are defensible market estimates (HIRA published average surgical costs plus inflation) that vary with hospital, stage, extent of surgery, complications, and drugs used.

This calculator is based on Korean rules (2026 National Health Insurance cancer special-case program for kidney cancer C64 and bladder cancer C67, Income Tax Act Article 59-4 medical expense tax credit, and market cost estimates for urologic cancer surgery, BCG, and systemic therapy). Figures are planning estimates, not medical advice, an insurer decision, or a hospital quote.